

1 Immuno-monitoring reveals an extended subclinical disease  
2 activity in tocilizumab-treated giant cell arteritis

---

3

4 Andrea Gloor<sup>1</sup>, Daniel Yerly<sup>1</sup>, Sabine Adler<sup>1</sup>, Stephan Reichenbach<sup>1,2</sup>, Stefan  
5 Kuchen<sup>1</sup>, Michael Seitz<sup>1</sup> and Peter M. Villiger<sup>1</sup>

6

7 <sup>1</sup>Department of Rheumatology, Immunology and Allergology, University Hospital, University  
8 of Bern, Bern, Switzerland

9 <sup>2</sup>Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland

10

11

12

13 Address for correspondence:

14 Professor Peter M. Villiger, MD

15 Head, Department of Rheumatology, Immunology and Allergology

16 University Hospital and, University of Bern, CH3010 Bern, Switzerland

17 E-mail: [peter.villiger@insel.ch](mailto:peter.villiger@insel.ch)

18 Tel +41 31 632 8015; Fax +41 31 632 9745

19

20

1 **Abstract**

2 **Objective:** Tocilizumab is effective in inducing and maintaining remission of Giant Cell  
3 Arteritis. Despite clinical and serological control of disease, magnetic resonance angiography  
4 may show persistence of inflammatory signals in arterial walls of unknown significance. Thus,  
5 there is an unmet need for tools to detect subclinical disease activity.

6 **Methods:** Immune-inflammatory markers in prospectively collected sera of the first RCT about  
7 tocilizumab in Giant Cell Arteritis were measured. As comparison sera of age- and sex-  
8 matched healthy volunteers were used. Biomarkers were quantified using luminex technology.

9 **Results:** From all parameters determined only MMP-3, pentraxin-3 and sTNFR2 were  
10 significantly elevated while ICAM-1 and CD163 were significantly decreased at early stages of  
11 the study, at time points of full clinical remission under treatment with tocilizumab plus  
12 glucocorticoids. In contrast, tocilizumab monotherapy towards the end of the study resulted in  
13 an almost complete normalization of immune-inflammatory molecules as compared to healthy  
14 controls. MMP-3 levels showed a weak association with magnetic resonance signal intensity;  
15 none of the biomarkers predicted relapse occurring within 6 months after study end.

16 **Conclusion:** The data document a subclinical disease activity in GCA which is more  
17 pronounced at early stages of treatment and almost disappears towards study end. They  
18 indicate that TCZ treatment of at least 52 weeks is necessary to reset a broad range of  
19 immune-inflammatory pathways.

20

1 **Key words:** giant cell arteritis, tocilizumab, glucocorticoids, biomarkers, disease activity,  
2 MMP-3

3 **Key messages:**

- 4 • Serological biomarkers document an extended subclinical disease activity in treated GCA  
5 during early remission  
6 • Prolonged inhibition of the IL-6 pathway using TCZ is not only abolishing signs and  
7 symptoms of the systemic inflammation but appears to reset a broad range of  
8 inflammatory mechanisms in GCA

9

10 Clinical trials registration: ClinicalTrials.gov NCT01450137

11 **Disclosure:** no author has declared a potential conflict of interest

12 **Funding:** The study was funded by the Research Funds of the Department of Rheumatology  
13 and Clinical Immunology, University Hospital (Inselspital) Bern, Switzerland

14 **Word count:** 3064 (without references)

## 1 **Introduction**

2 Giant Cell Arteritis (GCA) is the most frequent large vessel vasculitis (LVV) in Western  
3 countries, affecting predominantly women over 50 years of age [1,2]. It is histologically  
4 characterized by intense inflammation in all layers of the medium- to large-sized arteries and  
5 formation of granulomas. Risks are obliteration of the vascular lumen resulting in blindness  
6 and aneurysm formation with rupture of the aorta. Conventional treatment consists of high-  
7 dose and long-term glucocorticoids (GC), leading to side effects over time. Methotrexate helps  
8 to reduce the risk of relapse and to spare GCs [3]. Tocilizumab (TCZ) has very recently been  
9 proved to maintain remission and to lead to highly significant reduction of the cumulative GC  
10 dose [4,5].

11 Between 2012 and 2015 we performed the first phase 2, randomised, double blind, placebo-  
12 controlled trial (RCT) to define the role of TCZ to induce and control remission of GCA  
13 (ClinicalTrials.gov registration number: NCT01450137) [4]. Whereas all but one patient in the  
14 TCZ arm stayed in lasting remission up to study end at week 52, only 2 patients in the placebo  
15 arm did not relapse.

16 Patients with initial positive MR-angiography (MRA findings) underwent control MRA at weeks  
17 12 and 52. At week 12, three out of 9 TCZ patients (33%) showed normalization of vessel wall  
18 signals. At week 52, there was additional MRA improvement in some TCZ patients, but one-  
19 third showed persistent or increased late vessel wall enhancement despite clinical remission  
20 [6]. The significance of these “inflammatory” signals is currently unknown.

21 The protocol of the RCT included sampling of sera at the beginning and prior to every 4-weekly  
22 infusion, offering a unique opportunity to study a broad range of immune-inflammatory  
23 biomarkers prospectively in a very well characterized patient population. This was of particular  
24 interest as remission was initially induced by a combination of GC plus TCZ and maintained  
25 towards study end by TCZ in monotherapy.

26 The aims of this study were i) to search for and characterize a potential subclinical disease  
27 activity ii) to compare the biomarker profiles in early full remission under combined therapy  
28 with TCZ plus GCs and at late stage under TCZ monotherapy, iii) to search for markers  
29 associated with persistent MRA signals in vessel walls and iv) for markers predicting relapse  
30 within 6 months after study end.

## 31 **Methods**

### 32 **Patients and Controls**

33 Thirty patients aged 50 years or older suffering new-onset or relapsing GCA, confirmed by  
34 either temporal artery biopsy or by MR angiography (MRA), and meeting the 1990 American

1 College of Rheumatology criteria were included in the RCT [4]. Of these, 20 received TCZ  
2 which was dosed as to treat rheumatoid arthritis, i.e. 8mg/kg bodyweight i.v. in 4-weekly  
3 intervals. GC co-medication was started at a dose of 1mg/kg bodyweight and rapidly reduced  
4 thereafter: -0.1mg/kg bodyweight weekly until week 8, then -0.05mg/kg bodyweight weekly  
5 until week 12, followed by monthly -1mg/day. This reduction scheme resulted in a mean daily  
6 dose of 7mg prednisone at week 12 and a discontinuation of GC between months 9 and 11. A  
7 prior treatment with prednisolone up to 1mg/kg bodyweight for a maximum of 10 days between  
8 inclusion in the trial and the first infusion was permitted. Blood samples were collected at weeks  
9 0, 2, 4, 6, 8, 10, 12 and in 4-weekly intervals thereafter until week 52. The serum samples were  
10 immediately processed and stored in aliquots of 0.5ml at -70°C.

11 Sera of TCZ patients with relapse (N=1), serious adverse events (N=2) or with incomplete  
12 sampling (N=3) were excluded from analysis. Therefore, the longitudinally analyzed cohort  
13 comprised 14 TCZ patients in lasting remission for 52 weeks. Sera of patients in the placebo  
14 arm were purposely not analyzed as GC treatment had to be re-increased repeatedly, resulting  
15 in a very inhomogeneous patient population.

16 For every patient a serum of an age- and sex-matched healthy control was collected. These  
17 individuals lived on their own, they did neither take any regular medication, anti-inflammatory  
18 agent nor did they show signs of infection within 4 weeks of venipuncture.

### 19 **Biomarkers and Methods**

20 Based on recent studies and pathophysiological considerations a broad range of biomarkers  
21 was chosen (suppl. table). This included proteins of the TNF superfamily, of the IFN family, of  
22 T lymphocytes and regulatory T cells, monocytes, B lymphocytes, inflammatory markers such  
23 as hsCRP, adipocytokines and catabolic enzymes such as metalloproteinases (MMPs).  
24 Investigations were performed with luminex technology (R&DSYSTEMS, Minneapolis, USA and  
25 Invitrogen, Carlsbad, USA). Samples were quantified on a multiplex system (Bio-Plex 100  
26 array reader with Bio-Plex Manager software [version 6.1]; Bio-Rad, Hercules, CA, USA). If  
27 not specified, protein concentrations are given in pg/ml. In addition, TCZ, IL-6 and sIL-6  
28 concentrations were determined by an external company using luminex technology (QPS,  
29 Groningen, The Netherlands).

### 30 **MR-angiography and relapses**

31 MR signals were analyzed as described elsewhere [6]. In brief, MR angiography was repeated  
32 at 3 months and at study end if patients showed signs of mural inflammation at recruitment.  
33 Vessel wall signals were judged by two experienced radiologists in blinded fashion using the  
34 following grading: 0 = no mural thickening (maximal vessel wall thickness < 2.3 mm), no  
35 enhancement; 1 = no thickening, slight mural enhancement; 2 = mural thickening (> 2.3 mm),

1 significant mural enhancement; 3 = strong thickening (> 3 mm). Correlations were calculated  
2 between biomarkers and 21 MRA signals (7 patients treated with TCZ and available  
3 biomarkers with MRA examinations at all 3 time points).

#### 4 **Statistical Analysis**

5 Statistical analysis was performed using GraphPad Prism 5.0 software and IBM SPSS  
6 Statistics 21. Welch's correction was used to calculate significance between paired sample  
7 groups and Mann-Whitney U test between unpaired sample groups. Correlation analysis was  
8 done by calculation of Spearman rank's correlation coefficient. To search for biomarkers  
9 predicting flare and mural signal intensity, binary logistic regression and univariate receiver  
10 operating characteristic (ROC) curves were generated.

#### 11 **Ethical approval and patient informed consent**

12 The amendment to study 168/10 (ClinicalTrials.gov registration number: NCT01450137) was  
13 approved by the ethical commission of Bern, Switzerland, the 4. of May 2016 and the study  
14 was done in accordance with the Declaration of Helsinki. All patients gave written informed  
15 consent.

## 16 **Results**

### 17 **TCZ, IL-6 and sIL-6R**

18 TCZ levels approached steady state levels by the time of the 6th or 7th dose (figure 1A). Mean  
19 pre-dose levels of IL-6 initially increased in response to treatment with TCZ, and subsequently  
20 decreased to  $50.83 \pm 43.08$  by week 52 (figure 1B). Levels of sIL-6R levels increased almost  
21 immediately after initiation of dosing and appeared to reach a plateau after the 5th or 6th dose  
22 (figure 1C).

### 23 **Biomarkers not detectable in sera or without dynamic changes over time**

24 Eighteen molecules were not present at detectable levels (suppl. table). Remarkably, T-cell  
25 cytokines such as IL-2, IL17A and IFN- $\gamma$  were neither detectable prior to the first TCZ infusion  
26 nor at study end.

27 Several of the measured molecules showed a tendency to fluctuate but did not display a  
28 significant increase or decrease over time (suppl. table). Values of sTNFR2 and ICAM-1 did  
29 not show dynamic changes but differed compared to healthy controls (figure 2B). Osteopontin  
30 levels were slightly higher at study start and they became indistinguishable from controls at  
31 study end (P=0.44; not shown).

### 32 **Biomarkers with significant changes over time**

1 Pentraxin-3 and MMP-3 serum levels showed a remarkable decrease while CD163 exhibited  
2 a continuous increase over time, reaching almost normal values at the end of the study (figure  
3 2A). Pentraxin-3 started at a median concentration of 6342 (95% CI: 3965 - 8720) and  
4 decreased to 2807 (95% CI: 1993 - 3621;  $p=0.0002$ ). MMP-3 decreased from a median  
5 concentration of 76370 (95% CI: 65721 - 87018) to 27642 (95% CI: 21207 - 34077;  $p=0.0001$ ).  
6 MMP-3 levels showed a very homogeneous pattern with little inter-individual variation. At week  
7 4 MMP-3 values were indistinguishable from values before first TCZ infusion, thereafter a  
8 steady decrease could be noted to values close to normal. On the other hand, CD163 started  
9 at a median concentration of 892198 (95% CI: 628448 – 1155947), increased over time and  
10 equaled levels of healthy controls at the end of the study with a median concentration of  
11 1342169 (95% CI: 931206 - 1753133;  $p=0.0012$ ).

## 12 **Comparison between sera concentrations at study end and matched healthy controls**

13 Despite complete remission of disease, MMP-3, pentraxin-3 and sTNFR2 levels remained  
14 elevated, while ICAM-1 concentrations remained below levels of healthy matched controls  
15 (figure 2). At the end of the study the median serum concentration of MMP-3 (27642; 95% CI:  
16 21207 – 34077) remained higher compared to controls (19400; 95% CI: 14622 - 24178,  
17  $p=0.0353$ ). The same applies to pentraxin-3 (2807; 95% CI: 1993 – 3621) compared to  
18 controls (1491; 95% CI: 877 – 2105,  $p=0.0052$ ) and to sTNFR2 (267; 95% CI: 212 - 322)  
19 compared to controls (147; 95% CI: 120 – 174,  $p=0.0023$ ). The median serum concentration  
20 of ICAM-1 (1497851; 95% CI:  $1.11 \times 10^6$ - $1.89 \times 10^6$ ) on the other hand stayed below the median  
21 serum concentration of controls (2246971;  $1.83 \times 10^6$  –  $2.66 \times 10^6$ ,  $p=0.0134$ ).

## 22 **Correlation between biomarkers and MRA signals**

23 An association was found between MMP-3 concentration and the MRA signal intensity of the  
24 aortic wall as determined by MR angiography, but it did just not reach the level of significance  
25 ( $R^2_{adj}=0.13492$ ,  $p=0.0566$ ; suppl. figure 1). Calculation of the area under the curve (AUC) gave  
26 not a significant result (0.821; 95% CI: 0.616 – 1.000,  $p=0.093$ ). A serum concentration of  
27 MMP-3, equal or higher than 48843 was associated with a high mural signal intensity  
28 (sensitivity of 77% and specificity of 100%). Values equal or higher showed an effect size of  
29  $f^2=0.506$ , reflecting a strong effect of MMP-3 on mural signal intensity according to Cohen. But  
30 the chance to have a high mural signal intensity was not significantly higher with serum  
31 concentration equal or higher than 48843.

## 32 **Biomarkers associated with relapse after study end**

33 Patients relapsing within 6 months of study end are marked in red and with arrows in figure 2.  
34 Lower serum concentration of IL-6 and higher serum concentrations of pentraxin-3 were  
35 associated with a higher risk of a flare after study end. The AUC for IL-6 reached 0.764 (95%

1 CI: 0.523-1.000,  $p=0.068$ ). A serum concentration of IL-6, equal or higher than 29.45 was  
2 slightly associated with flare after study end (sensitivity of 87.5% and specificity of 55.6%). The  
3 relative risk to flare after study end was 4.44 times higher for serum concentration over 29.45.  
4 For pentraxin-3 the AUC reached 0.646 (95% CI: 0.372-0.920,  $p=0.312$ ). A threshold of 2241  
5 showed a sensitivity of 66.7% and a specificity of 62.5%. The relative risk to flare after study  
6 end was 1.88 times for a serum concentration over 2241.

### 7 **Correlation of different biomarker and TCZ serum levels**

8 Table 1 shows correlations between six biomarkers and TCZ: IL-6 concentrations directly  
9 correlate with TCZ levels ( $r=-0.5585$ ,  $p<0.0001$ ), while MMP-3 and pentraxin-3 correlates  
10 inversely with TCZ serum level (MMP-3:  $r=-0.5806$ ,  $p<0.0001$ , and pentraxin-3:  $r=-0.3855$ ,  
11  $p=0.0044$ , respectively).

12 Several direct and inverse correlations between the six biomarkers could be observed: MMP-  
13 3 and pentraxin-3 showed an inverse correlation with IL-6 ( $r=-0.6119$ ,  $p<0.0001$  and  $r=-0.4158$ ,  
14  $p=0.0033$ , respectively). MMP-3 and pentraxin-3 serum levels were directly correlated to each  
15 other ( $r=0.4637$ ,  $p=0.0005$ ). sTNFR2 also correlated inversely with IL-6 ( $r= -0.3748$ ,  $p=0.0087$ ),  
16 while CD163 demonstrated a positive correlation with IL-6 ( $r=0.3327$ ,  $p= 0.0208$ ). In agreement  
17 with the positive correlation between CD163 and IL-6, pentraxin-3 and CD163 showed an  
18 inverse correlation to each other ( $r=-0.0.2826$ ,  $p=0.0403$ ). ICAM-1 was the only biomarker  
19 which showed neither a correlation to TCZ serum level nor to other biomarkers.

### 20 **Discussion**

21 Two recent RCTs showed effectiveness of TCZ in controlling GCA [4,5]. Both documented a  
22 highly significant and clinically relevant sparing effect on GCs. Despite these convincing data,  
23 questions beyond the clinical outcome remain. In particular MRA documented persistence of  
24 late-enhancement in arterial wall of several patients [6]. It is currently unknown, whether these  
25 signals reflect arterial wall inflammation or rather represent persistent hyperaemia. The  
26 quantification of a wide range of immune inflammatory markers may shed light on potential  
27 subclinical disease, explain MRA signals and predict relapse after study end.

28 Due to the fact that all but two patients in the placebo arm suffered relapse(s), the GC doses  
29 had to be re-increased repeatedly resulting in a highly heterogeneous population. As a  
30 consequence the placebo arm could not serve as a meaningful control. Thus, the presented  
31 data characterize the longitudinal evolution of subclinical biological activity only. Whether GC  
32 monotherapy would have resulted in comparable changes is not known.

33 The rise in IL-6 levels after the first dose is typically seen after administration of TCZ and is  
34 hypothesized to occur due to displacement of IL-6 as TCZ binds to the soluble and membrane  
35 bound IL-6 receptors [7]. The slow increase of TCZ trough levels implicates a delayed control

1 of the disease by the biologic agent and suggests a central therapeutic role of GC at early  
2 stages of the study. Remarkably, the only relapse in the TCZ arm happened in week 11 at a  
3 time when GC were substantially reduced and TCZ had not yet reached steady state trough  
4 levels. New treatment protocols should respect these findings.

5 Soluble TNFR2 was proposed as marker of subclinical disease activity in a variety of  
6 autoimmune diseases [8,9,10]. In GCA, however, its performance has not been analysed. In  
7 this study sTNFR2 levels fluctuated over time and they did not predict relapse. The inter-  
8 individual differences are in line with the literature, however, the intra-individual changes  
9 remain unexplained. Pentraxin-3 levels have been shown to be associated with vascular  
10 inflammation in GCA identifying patients with very recent optic nerve ischemia or recent  
11 diagnosis [11]. The values of our study show a steady decrease over time with near  
12 normalisation at study end. ICAM-1 concentrations, on the other hand, remained below levels  
13 of healthy controls throughout the study. An earlier study documented a rapid fall of ICAM-1  
14 concentration upon GC treatment which persisted over the whole study period and reflected  
15 clinical remission [12]. The low ICAM-1 levels at start of our study may be explained by the  
16 fact that patients were allowed for GC treatment before first TCZ infusion of up to 10 days.  
17 Findings of a more recent trial about infliximab to treat GCA showed increased levels of ICAM-  
18 1 near relapse [13]. As our patients did not show relapses, our findings are in good agreement  
19 with these data and they suggest a sufficient immunosuppression by TCZ monotherapy.  
20 sCD163 has recently been shown to reflect disease activity in a variety of auto-inflammatory  
21 diseases, e.g. of Rheumatoid Arthritis [14]. The subnormal values at early time points of our  
22 study may be understood as a profound anti-inflammatory effect of combined GC and TCZ,  
23 whereas the gradual increase to normal values under TCZ monotherapy suggests  
24 reconstitution of homeostasis. A very recent study reports about serum osteopontin as a  
25 biomarker of disease activity in GCA and a potential predictor of relapse [15]. Remarkably, our  
26 findings show an identical range of initial values and comparable values in remission, however  
27 significance was not reached. Due to the lack of relapses, we cannot comment about the value  
28 of this biomarker to predict relapse. Collectively, the data of these biomarkers document an  
29 ongoing subclinical disease activity with quantitative and qualitative changes over time.

30 Neutralization of IL-6 blunts the acute phase response. The fact that control of the IL-6 pathway  
31 using TCZ is sufficient to induce remission in immunologically complex diseases such as  
32 rheumatoid arthritis strongly argues for additional indirect effects, e.g. on the recruitment of  
33 pathogenic T helper cells. Indeed, studies have documented that TCZ abrogates generation  
34 of TH17 cells in rheumatoid arthritis [16]. In GCA, TH1 and TH17 cells as well as the  
35 CD161+CD4+ precursor cells have been shown to be massively increased in the arterial wall,  
36 whereas Treg cells are reduced locally and in blood [17]. GC treatment suppresses the TH17  
37 but not the TH1 arm in the blood and the vascular lesions [18]. Very recent data showed that

1 TCZ normalizes deranged function of Treg cells [19]. The fact that we could detect neither IL-  
2 17 nor any TH1 cytokines in sera is in line with these findings.

3 Metalloproteinases play an important role in vessel wall inflammation and destruction of elastic  
4 fibres [20,21]. IL-6 has been shown to induce production of the tissue inhibitor of  
5 metalloproteinases (TIMP) [22,23], and GC have been shown to induce MMP-3 [24]. These  
6 findings imply that neutralization of IL-6 as well as treatment with GC may lead to uncontrolled  
7 activity of catabolic enzymes and propagation of vessel wall destruction, and - in addition -  
8 they may serve as an explanation for the known risk of perforation of diverticulitis under dual  
9 immunosuppression in GCA. In this regard, the measured levels of metalloproteinase 3 are of  
10 particular interest. As displayed in figure 2, the values show a uniform pattern over time with  
11 little inter-individual variation. Furthermore, their values decrease significantly towards study  
12 end. Most intriguingly, the MMP-3 values in week 4 are indistinguishable from the values prior  
13 to the first infusion of TCZ, although all patients were in full remission at this time point. The  
14 values at week 4, therefore, reflect the combined effect of TCZ plus 0.6mg/kg bodyweight of  
15 prednisone, whereas at week 52 patients are on TCZ monotherapy. Taken together, these  
16 data argue that targeted inhibition of the IL-6 pathway is sufficient to control destructive effector  
17 mechanisms. The contradictory results from cell studies and our clinical trial can be reconciled  
18 by the hypothesis of indirect effects of TCZ, which eventually overrule the direct effects of IL-  
19 6 on TIMP expression.

20 The correlations between sera concentrations of sTNFR2, ICAM-1, pentraxin-3, CD163, MMP-  
21 3 and MRA signals revealed an interesting association between MMP-3 levels and mural signal  
22 intensity. Higher levels of pentraxin-3 and lower levels of IL-6 showed a weak correlation with  
23 relapse within 6 months after study end. Collectively, however, the data regarding MRA signals  
24 and relapse do not suggest that one or a set of analysed biomarkers will emerge as a clinical  
25 tool to guide treatment.

26 They main weakness of this study is the small sample size and the lack of a control population.  
27 This is partially counterbalanced by the fact that patients are characterized in great detail and  
28 sera were collected in the context of an RCT.

29 In summary our study documents an extended and persistent subclinical disease activity in  
30 GCA which is more pronounced at early stages of treatment and almost disappears towards  
31 study end. Inhibition of the IL-6 pathway is not only abolishing signs and symptoms of the  
32 systemic inflammation, but prolonged treatment with TCZ appears to reset a range of  
33 inflammatory mechanisms. The data are in line with recent findings about effects of TCZ on  
34 Th-17 and Treg generation and function.

### 35 **Declaration of interests**

36 The authors declare no conflicts interests.

## 1 **Acknowledgements**

2 We thank Diana Dan and Felix Wermelinger for patient care and processing of sera samples,  
3 Sandra Gsponer for laboratory assistance and Frauke Foerger and Lukas Bütikofer, statistician  
4 of the Clinical Trial Unit of the University of Bern, for advice and supervision of statistical  
5 calculations.

## 6 **References**

- 7 1. Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology,  
8 geoepidemiology and treatment. *Autoimmun Rev.* 2012;11(6-7):A544-54.
- 9 2. Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica.  
10 *N Engl J Med.* 2014;371(1):50-7.
- 11 3. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP,  
12 et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data  
13 meta-analysis. *Arthritis Rheum.* 2007;56(8):2789-97.
- 14 4. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for  
15 induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-  
16 blind, placebo-controlled trial. *Lancet.* 2016;387(10031):1921-7.
- 17 5. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of  
18 Tocilizumab in Giant-Cell Arteritis. *N Engl J Med.* 2017;377(4):317-28.
- 19 6. Reichenbach S, Adler S, Cullmann J, *et al.* Tocilizumab for the Treatment of Giant Cell  
20 Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial  
21 [abstract]. *Rheumatology*, accepted.  
22
- 23 7. Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current  
24 perspective. *Curr Opin Rheumatol.* 2011;23(3):273-7.
- 25 8. Wais T, Fierz W, Stoll T, Villiger PM. Subclinical disease activity in systemic lupus  
26 erythematosus: immunoinflammatory markers do not normalize in clinical remission. *J*  
27 *Rheumatol.* 2003;30(10):2133-9.
- 28 9. Cantarini L, Pucino V, Vitale A, Talarico R, Lucherini OM, Magnotti F, et al.  
29 Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with  
30 epidemiological profile, disease activity and therapeutic regimens. *Clin Exp Immunol.*  
31 2016;184(2):197-207.
- 32 10. Turan B, Gallati H, Erdi H, Gürler A, Michel BA, Villiger PM. Systemic levels of the T cell  
33 regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological  
34 marker of disease activity. *J Rheumatol.* 1997;24(1):128-32.
- 35 11. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-González S, et al.  
36 Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular  
37 endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia.  
38 *Arthritis Rheum.* 2012;64(3):854-65.


- 1 12. Macchioni P, Boiardi L, Meliconi R, Salvarani C, Grazia Ugucioni M, et al. Elevated soluble  
2 intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica:  
3 influence of steroid treatment. *J Rheumatol.* 1994 Oct;21(10):1860-4.
- 4 13. Visvanathan S, Rahman MU, Hoffman GS, Xu S, García-Martínez A, Segarra M, et al.  
5 Tissue and serum markers of inflammation during the follow-up of patients with giant-cell  
6 arteritis-a prospective longitudinal study. *Rheumatology (Oxford).* 2011;50(11):2061-70.
- 7 14. Greisen SR, Møller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker  
8 P, et al. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis:  
9 association with disease activity but different response patterns to synthetic and biologic  
10 DMARDs. *Clin Exp Rheumatol.* 2015 Jul-Aug;33(4):498-502.
- 11 15. Prieto-González S, Terrades-García N, Corbera-Bellalta M, Planas-Rigol E, Miyabe C,  
12 Alba MA, et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing  
13 course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated  
14 patients. *RMD Open.* 2017 Dec 22;3(2):e000570. doi: 10.1136/rmdopen-2017-000570.  
15 eCollection 2017.
- 16 16. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, et al. Interleukin-6  
17 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17  
18 responses. *Arthritis Rheum.* 2008;58(12):3710-9.
- 19 17. Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17  
20 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia  
21 rheumatica pathogenesis. *Arthritis Rheum.* 2012 Nov;64(11):3788-98.
- 22 18. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses  
23 in giant cell arteritis. *Circulation.* 2010;121(7):906-15.
- 24 19. Miyabe C, Miyabe Y, Strle K, Kim ND, Stone JH, Luster AD, et al. An expanded population  
25 of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.  
26 *Ann Rheum Dis.* 2017;76(5):898-905.
- 27 20. Weyand CM, Wagner AD, Björnsson J, Goronzy JJ. Correlation of the topographical  
28 arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis.  
29 *J Clin Invest.* 1996;98(7):1642-9.
- 30 21. Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-  
31 Tarres M. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling.  
32 *Circulation.* 2005;112(2):264-9.
- 33 22. Lotz M, Guerne PA. Interleukin-6 induces the synthesis of tissue inhibitor of  
34 metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). *J Biol Chem.*  
35 1991;266(4):2017-20.
- 36 23. Silacci P, Dayer JM, Desgeorges A, Peter R, Manueddu C, Guerne PA. Interleukin (IL)-6  
37 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and  
38 block IL-1-induced collagenolytic activity. *J Biol Chem.* 1998;273(22):13625-9.
- 39 24. Hathout Y, Conklin LS, Seol H, Gordish-Dressman H, Brown KJ, Morgenroth LP, et al.  
40 Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. *Sci Rep.*  
41 2016;6:31727.

## 1 Figure legends


2 Figure 1. Serum concentrations of TCZ, IL-6 and sIL-6. Serum concentration at each sampling  
3 time point with mean  $\pm$  SD ( $\pm$  SE for sIL-6R) of 17 patients treated with TCZ

4


### A TCZ serum concentration



### B IL-6 serum concentration




### C sIL-6R serum concentration




5

- 1 Figure 2. Serum concentration of sTNFR2, ICAM-1, CD163, MMP-3 and pentraxin-3. Serum
- 2 concentration from 14 patients treated with TCZ over the time in comparison with 14 age- and
- 3 sex-matched healthy volunteers (Ctrl). Patients with relapse after study end are marked in red
- 4 and with arrows



- 1 Supplementary figure 1. Correlation between level of MMP-3 and mural signal intensity in MR-
- 2 angiography



3

4

1 **Tables**

2 **Table 1: Spearman's rank correlation between different biomarker and TCZ serum**  
3 **levels**

	ICAM-1	sTNFR2	CD163	pentraxin-3	MMP-3	IL-6
Toclizumab serum level	ns	ns	ns	p=0.0044 r <-0.25	p<0.0001 r <-0.5	p<0.0001 r >0.5
IL-6	ns	p=0.0087 r <-0.25	p=0.0208 r >0.25	p=0.0033 r <-0.25	p<0.0001 r <-0.5	
MMP-3	ns	ns	ns	p=0.0005 r >0.25		
pentraxin-3	ns	ns	p=0.0403 r <-0.25			
CD163	ns	ns				
sTNFR2	ns					

4 a. r= Spearman's rank coefficient; positive correlation if r>0 and negative correlation if r<0  
5 b. ns= correlation not significant  
6

7

8

1 supplementary table

undetectable Biomarkers (N=18)		Biomarkers with non-significant change over time (N=23)		Biomarkers with significant change over time (5)
IL-2	IL-34	APRIL / TNFSF13	MMP-2	Pentraxin-3
IL-10	IL-32	BAFF / TNFSF13B	ICAM-1	MMP-3
IL-11	IL-29/IFN- $\lambda$ 1	sCD30 / TNFRSF8	hsCRP	sCD163
IL-12(p40)	IL-28A/ IFN- $\lambda$ 2	Chitinase-3-like1/YKL-40	Osteopontin	IL-6
IL-12(p70)	IL-27(p28)	gp130 / sIL-6R $\beta$	sTNFR1	sIL-6R
IL17A	IFN- $\gamma$	IFN- $\alpha$ 2	sTNFR2	
IL-20	MMP-1	IFN- $\beta$	TSLP	
IL-22	Osteocalcin	sCD25/IL-R2	TWEAK / TNFSF12	
IL-26	VCAM-1	IL-8	Leptin	
		IL-19	Resistin	
		IL-35	Adiponectin	
		LIGHT / TNFSF14		

2

3